Skip to main content
SpringerLink
Log in

Trastuzumab

A Viewpoint by Mark Pegram

  • Adis New Drug Profile
  • Guest Commentary
  • Published:
BioDrugs Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Slamon DJ; Clark GM; Wong SG, et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987 Jan 9; 235(4785): 177–82

    Article  PubMed  CAS  Google Scholar 

  2. Slamon DJ; Godolphin W; Jones LA, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science, 1989 May 12; 244(4905): 707–12

    Article  PubMed  CAS  Google Scholar 

  3. Clark GM; McGuire WL. Follow-up study of HER-2/neu amplification in primary breast cancer. Cancer Res 1991 Feb 1; 51(3): 944–8

    PubMed  CAS  Google Scholar 

  4. Lovekin C; Ellis IO; Locker A, et al. c-erbB-2 oncoprotein expression in primary and advanced breastcancer. Br J Cancer 1991 Mar; 63(3): 439–43

    Article  PubMed  CAS  Google Scholar 

  5. Reese DM; Slamon DJ. HER-2/neu signal transduction in human breast and ovarian cancer. Stem Cells 1997; 15(1): 1–8

    Article  PubMed  CAS  Google Scholar 

  6. Fendly BM; Winget M; Hudziak RM et al. Characterization of murine monoclonal antibodies reactive to either the human epidermal growth factor receptor or HER2/neu gene product. Cancer Res 1990 Mar 1; 50(5): 1550–8

    PubMed  CAS  Google Scholar 

  7. Lewis GD; Figari I; Fendly B, et al. Differential responses of human tumor cell lines to anti-p185HER2 monoclonal antibodies. Cancer Immunology, Immunotherapy 1993 Sep; 37(4): 255–63

    Article  PubMed  CAS  Google Scholar 

  8. Carter P; Presta L; Gorman CM, et al. Humanization of an anti-p185HER2 antibody for human cancer therapy. Proceedings of the National Academy of Sciences of the United States of America, 1992 May 15; 89(10): 4285–9

    Article  PubMed  CAS  Google Scholar 

  9. Pegram MD, Baly D, Wirth C, et al., Antibody dependent cell-mediated cytotoxicity in breast cnacer patients in phase III clinical trials of a humanized anti-HER2 antibody [abstract 4044]. Proc Am Assoc Cancer Res 1997; 38: 602

    Google Scholar 

  10. Pietras RJ; Fendly BM; Chazin VR, et al. Antibody to HER-2/neu receptor blocks DNA repair after cisplatin in human breast and ovarian cancer cells. Oncogene 1994 Jul; 9(7): 1829–38

    PubMed  CAS  Google Scholar 

  11. Pegram M, Hsu S, Pietras R, et al. Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers. Oncogene 1999. In press

  12. Roche PC, Ingle JN. Increased HER2 with U.S. Food and Drug Administration-approved antibody [letter]. J Clin Oncol 1999; 17: 434–5

    PubMed  CAS  Google Scholar 

  13. Lee KF; Simon H; Chen H, et al. Requirement for neuregulin receptor erbB2 in neural and cardiac development. Nature 1995 Nov 23; 378(6555): 394–8

    Article  PubMed  CAS  Google Scholar 

  14. Buhring HJ; Sures I; Jallal B, et al. The receptor tyrosine kinase pl85HER2 is expressed on a subset of B-lymphoid blasts from patients with acute lymphoblastic leukemia and chronic myelogenous leukemia. Blood 1995 Sep 1; 86(5): 1916–23

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Hematology/Oncology, The University of California Los Angeles, Los Angeles, California, USA

    Mark Pegram

Authors
  1. Mark Pegram
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Pegram, M. Trastuzumab. BioDrugs 12, 136 (1999). https://doi.org/10.2165/00063030-199912020-00005

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00063030-199912020-00005

Keywords

Search

Navigation